The rare disease therapeutic landscape has evolved rapidly over the last decade, driven by advances in biologics, cell and gene therapies, personalized medicines, and targeted treatments. As rare disease development activity increases, many emerging biotech companies are working with highly specialized products intended for extremely small patient populations. In the United States, the Orphan Drug Act defines a rare disease as one that affects less than 200,000 people in the country. 

While these therapies offer tremendous potential for patients with unmet medical needs, they also introduce unique manufacturing challenges—particularly during sterile fill-finish operations.

Unlike traditional large-scale pharmaceutical manufacturing, rare disease therapies are often produced in very small batches using limited quantities of highly valuable active pharmaceutical ingredient (API) or drug substance. In many cases, product loss during manufacturing is not simply a financial concern; it may directly impact clinical timelines, patient access, or the viability of an entire development program.

Successfully manufacturing these products requires a fundamentally different approach to aseptic processing—one centered around flexibility, precision, sterility assurance, and minimizing material loss at every stage of production.

This paper explores the fill-finish challenges associated with rare disease drug products and highlights strategies that can help developers successfully navigate small-batch sterile manufacturing, including:

• Minimizing loss through fill-finish and analytical testing process design
• Understanding the impact of filling environment on sterility
• Understanding regulatory expectations for these specialized therapy types
• Highlighting considerations for choosing the right CDMO for rare disease fill-finish

Download whitepaper

Enabling Rare Disease Therapies

Phone

This field is for validation purposes and should be left unchanged.

Name(Required)

First name Last name

Email(Required)

Company(Required)

At Sharp, we always have exciting pharma topics that we’d like to share with you. We will only contact you about topics that we think might be of interest, based on the information you provide to us.

Yes, I’d like to receive email updates from Sharp based on my details [1]

[1] Sharp takes your privacy seriously and will only use your personal information to provide services that you have requested from us. We will not share your personal information with non-agent third parties. View our privacy policy here.

This field is hidden when viewing the form

utm_source

This field is hidden when viewing the form

utm_medium

This field is hidden when viewing the form

utm_campaign

This field is hidden when viewing the form

Post Title

Submit